Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Key Highlights
- ➤Peptide therapeutics market projected to reach $334.95 billion by 2034
- ➤Roche’s enicepatide cut HbA1c 2.65% and weight 15.5% at 48 weeks
- ➤Novo Nordisk will present 26 obesity-portfolio abstracts at ObesityWeek 2026
- ➤Viking launched Phase 3 trials for once-daily oral VK2735
- ➤Lilly raised 2026 guidance after Q3 results exceeded prior expectations
Expert Statements
Pratap Sandhu, CEO of The Precision Peptide Company
“Last week we announced 16 prescription therapies, all compounded in the United States. HHS has now set out a framework for six widely used peptides, led by BPC-157, concerning the U.S. 503A pathway, with verified sourcing, lot-level testing and safety reporting built in. Just as important, it recognizes oral, topical and intranasal routes alongside injection. Needle-free first, every format available, has been our approach from day one.”
Martin Holst Lange, Chief scientific officer and executive vice president, Research & Development at Novo Nordisk
“Obesity is a complex disease, and people living with obesity can have different experiences and treatment needs at different stages of life. At ObesityWeek(®), we will share findings across several key areas, including: investigational CagriSema; real-world treatment experience with oral and injectable Wegovy(®); and investigational semaglutide injection in children ages 6 to under 12. Studying treatment options across different settings, formulations, outcomes, and dosing regimens can strengthen understanding of obesity and help inform progress in line with Novo's commitment to lasting health.”
David A. Ricks, Chair and CEO of Eli Lilly and Company
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia. Lilly is executing well across the value chain, and our potential for impact on human health continues to expand.”
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic disorders and other serious diseases. The opportunity is getting harder to ignore. According to Fortune Business Insights, the global peptide therapeutics market is projected to grow from approximately $146.34 billion in 2026 to $334.95 billion by 2034. That is a substantial expansion in a market being fueled by successful GLP-1 drugs, growing demand for targeted therapies and continued advances in peptide research. What was once a specialized area of drug development is quickly becoming a major force in the pharmaceutical industry. Those targeting Biotech and Wellness growth should watch these Companies poised to capitalize on Expanding Markets and Emerging Opportunities: The Precision Peptide Company Inc. (OTCQB: PNGAF) (CSE: BPC), Roche (OTCQX: RHHBY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics, Inc. (NASDAQ: VKTX), Eli Lilly and Company (NYSE: LLY).
Get started
Create a free account to read the full story.